Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 27
- Registration Number
- NCT00449761
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Hackensack University Medical Center/Oncology Research Dept., Hackensack, New Jersey, United States
🇺🇸Indiana Blood and Marrow Institute/St. Francis Hospital, Beech Grove, Indiana, United States
Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 17
- Registration Number
- NCT00448396
Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT00446511
- Locations
- 🇫🇷
Sites in France, France, France
🇮🇳Sites in India, India, India
🇵🇱Sites in Poland, Poland, Poland
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 85
- Registration Number
- NCT00446082
- Locations
- 🇳🇴
Novartis Investigative Site, Oslo, Norway
🇺🇸Cedars Sinai Medical Center SC - 4, Los Angeles, California, United States
🇺🇸Stanford University Medical Center Stanford Cancer Center (3), Stanford, California, United States
Lapatinib and Bevacizumab for Metastatic Breast Cancer
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT00444535
- Locations
- 🇺🇸
Novartis Investigative Site, Sleepy Hollow, New York, United States
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2021-07-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 38
- Registration Number
- NCT00445068
- Locations
- 🇺🇸
Aptium Oncology, Berkeley, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸City of Hope, Duarte, California, United States
Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
- First Posted Date
- 2007-03-07
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 518
- Registration Number
- NCT00443898
- Locations
- 🇺🇸
Dr. Diane Baker, Lake Oswego, Oregon, United States
🇺🇸Dr. Kevin Terry, Lutherville, Maryland, United States
🇺🇸Dr. Harry Penny, Altoona, Pennsylvania, United States
Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail
- First Posted Date
- 2007-03-06
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 526
- Registration Number
- NCT00443820
- Locations
- 🇺🇸
Dr. John Mallory, Overland Park, Kansas, United States
🇺🇸Dr. Max Weisfeld, Baltimore, Maryland, United States
🇺🇸Dr. Jeffrey Conrow, Topeka, Kansas, United States
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies (Extension)
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00442741
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT00441610
- Locations
- 🇯🇵
Novartis Investigative Site, Chiba, Japan